Tecfidera 120 mg dimethyl fumarate Capsules × 14

TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

How to use:

• Starting dose: 120 mg twice a day, orally, for 7 days
• Maintenance dose after 7 days: 240 mg twice a day, orally
• Swallow TECFIDERA capsules whole and intact. Do not crush, chew, or sprinkle capsule contents on food

Caution & Warnings:

• Anaphylaxis and angioedema: Discontinue and do not restart TECFIDERA if these occur.
• Progressive multifocal leukoencephalopathy (PML): Withhold TECFIDERA at the first sign or symptom suggestive of PML.
• Herpes zoster and other serious opportunistic infections: Consider withholding TECFIDERA in cases of serious infection until the infection has resolved.
• Lymphopenia: Obtain a CBC including lymphocyte count before initiating TECFIDERA, after 6 months, and every 6 to 12 months thereafter. Consider interruption of TECFIDERA if lymphocyte counts <0.5 x 109/L persist for more than six months.
• Liver injury: Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating TECFIDERA and during treatment, as clinically indicated. Discontinue TECFIDERA if clinically significant liver injury induced by TECFIDERA is suspected.